ライフサイエンスコーパス: golimumab

1 umab and the TNF-inhibitors certolizumab and golimumab).

2 n = 1, abatacept; n = 3, tocilizumab; n = 5, golimumab).

3 is and final containment of the disease with golimumab.

4 nders in the induction study received 100 mg golimumab.

5 Alternatives to infliximab are ADA and golimumab.

6 benefit was maintained through week 52 with golimumab.

7 ylosing spondylitis from phase III trials of golimumab.

8 ated with a lower incidence of antibodies to golimumab.

9 ebo (n = 113), golimumab 50 mg (n = 146), or golimumab 100 mg (n = 146) every 4 weeks through week 20

10 limumab 50 mg, and 45% of patients receiving golimumab 100 mg achieved an ACR20 response (the primary

11 mg, golimumab 50 mg increased to 100 mg, and golimumab 100 mg continued at 100 mg.

12 ve subcutaneous placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks through week 20.

13 olimumab 50 mg group and 58% of those in the golimumab 100 mg group had at least 75% improvement in t

14 p 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg plus MTX (group 4).

15 p 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg plus MTX (group 4).

16 igned to receive placebo plus MTX (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg

17 mized to receive placebo plus MTX (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg

18 during the study period: adalimumab (1,260), golimumab (111), infliximab (1,035), tofacitinib (17), u

19 = .004 and P = .002, respectively) or 50 mg golimumab (23.2% and 41.7%, respectively).

20 es were highest among those who had received golimumab 4 mg/kg plus MTX (70% and 48%, respectively).

21 week 54 in 47.0% of patients receiving 50 mg golimumab, 49.7% of patients receiving 100 mg golimumab,

22 ubcutaneous injections of placebo (n = 113), golimumab 50 mg (n = 146), or golimumab 100 mg (n = 146)

23 HS from baseline to week 24 for the combined golimumab 50 mg and 100 mg group (-0.09) and the golimum

24 ndomized: 113 to placebo and 146 each to the golimumab 50 mg and 100 mg groups.

25 enter the early escape phase crossed over to golimumab 50 mg at week 24.

26 mumab 50 mg and 100 mg group (-0.09) and the golimumab 50 mg group (-0.16) were significantly differe

27 y psoriasis at baseline, 40% of those in the golimumab 50 mg group and 58% of those in the golimumab

28 , with placebo crossover to golimumab 50 mg, golimumab 50 mg increased to 100 mg, and golimumab 100 m

29 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg

30 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg

31 ceiving golimumab, 51% of patients receiving golimumab 50 mg, and 45% of patients receiving golimumab

32 arly escape phase, with placebo crossover to golimumab 50 mg, golimumab 50 mg increased to 100 mg, an

33 ly assigned to receive subcutaneous placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks throu

34 Golimumab (50 mg or 100 mg) maintained clinical response

35 At week 14, 48% of all patients receiving golimumab, 51% of patients receiving golimumab 50 mg, an

36 Subcutaneous golimumab, a fully human monoclonal antibody to tumor ne

37 , tofacitinib 5 mg, infliximab, vedolizumab, golimumab, adalimumab, and ustekinumab, respectively.

38 0,049, $12,059, and $0 for tofacitinib 5 mg, golimumab, adalimumab, tofacitinib 10 mg, infliximab, us

39 Golimumab, administered subcutaneously every 4 weeks, ha

40 plus MTX is better than, and the efficacy of golimumab alone is similar to, the efficacy of MTX alone

41 ents who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative c

42 failure, all in patients who received 100 mg golimumab) and 4 developed active tuberculosis.

43 olimumab, 49.7% of patients receiving 100 mg golimumab, and 31.2% of patients receiving placebo (P =

44 his study, alternative biologics (abatacept, golimumab, and tocilizumab) were useful for treating CAU

45 b, infliximab, methotrexate, apremilast, and golimumab are recommended.

46 at new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and m

47 placebo plus MTX or intravenous infusions of golimumab at a dose of 2 mg/kg or 4 mg/kg, with or witho

48 Treatment with golimumab at doses of 50 mg and 100 mg significantly imp

49 Methotrexate (MTX)-naive patients (in the Golimumab Before Employing Methotrexate as theFirst-Line

50 Whether golimumab could preserve beta-cell function in youth wit

51 ly include mAbs (infliximab, adalimumab, and golimumab), either chimeric or human in sequence, a PEGy

52 tions of placebo plus MTX or 50 mg or 100 mg golimumab every 2 or 4 weeks plus MTX through week 48.

53 9% of patients in the group receiving 100 mg golimumab every 2 weeks achieved an ACR20 response (P<0.

54 given placebo or injections of 50 or 100 mg golimumab every 4 weeks through week 52.

55 went randomization - 56 were assigned to the golimumab group and 28 to the placebo group.

56 ere reported in 13 participants (23%) in the golimumab group and in 2 (7%) of those in the placebo gr

57 ) was observed in 43% of participants in the golimumab group and in 7% of those in the placebo group

58 t week 52 differed significantly between the golimumab group and the placebo group (0.64+/-0.42 pmol

59 se, and the PsA-modified MASES index in each golimumab group compared with placebo.

60 e in the primary end point when the combined golimumab groups and at least 1 of the individual dose g

61 e reported in 9% of patients in the combined golimumab groups and in 6% of patients in the placebo gr

62 rative colitis; patients who received 100 mg golimumab had clinical remission and mucosal healing at

63 om phase 3 clinical trials of infliximab and golimumab, high pretreatment expression of OSM is strong

64 s with active RA despite MTX therapy (in the Golimumab in Active Rheumatoid Arthritis Despite Methotr

65 gests the use of infliximab, adalimumab, and golimumab in combination with an immunomodulator over co

66 Golimumab in combination with MTX inhibited radiographic

67 vities and HRQoL in UC patients treated with golimumab in Germany.

68 reported for other TNFalpha antagonists and golimumab in other approved indications.

69 Among all patients given golimumab in the study, 3 died (from sepsis, tuberculosi

70 concerning the treatment with TNFa inhibitor golimumab in UC patients are still rare.

71 the long-term efficacy and safety of ADA and golimumab in ulcerative colitis.

72 ccess of ABT (abatacept, tocilizumab, and/or golimumab) in children failing conventional treatment.

73 nt mAbs, such as Infliximab, Adalimumab, and Golimumab, in blood serum samples in a one-step process,

74 spite conventional therapy, who responded to golimumab induction therapy.

75 double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Coliti

76 om 8.2 (SD: 17.6, BL) to 0.7 (SD: 2.1) after golimumab induction.

77 owed that all biological agents (adalimumab, golimumab, infliximab, and vedolizumab) resulted in more

78 b, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab, and ustekinumab.

79 Treatment of PsA with golimumab inhibited structural damage progression and de

80 Golimumab is a human monoclonal antibody specific for tu

81 Golimumab leads to notable long-term improvements in wor

82 n ACR50 response between the group receiving golimumab monotherapy and the group receiving placebo pl

83 ents who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups giv

84 ding an adequate assessment of the effect of golimumab on radiographic progression in this study.

85 vert type 1 diabetes to receive subcutaneous golimumab or placebo for 52 weeks.

86 Subcutaneous injections of golimumab or placebo were administered every 4 weeks.

87 Golimumab orplacebo was administered subcutaneously ever

88 However, intravenously administered golimumab plus MTX appears to have benefit in the longer

89 observed in 21% of the patients treated with golimumab plus MTX compared with 13% of the patients tre

90 The combination of golimumab plus MTX demonstrated a significantly better r

91 ixty-one percent of patients in the combined golimumab plus MTX dose groups achieved an ACR20 respons

92 Golimumab plus MTX effectively reduces the signs and sym

93 24, significantly more patients treated with golimumab plus MTX had achieved an ACR50 response.

94 y measures demonstrated that the efficacy of golimumab plus MTX is better than, and the efficacy of g

95 ong patients given placebo, 50 mg, or 100 mg golimumab, respectively; percentages of serious infectio

96 with newly diagnosed overt type 1 diabetes, golimumab resulted in better endogenous insulin producti

97 Insulin use was lower with golimumab than with placebo.

98 Three months after initiation of golimumab therapy, total work productivity impairment (T

99 -related costs than those taking adalimumab, golimumab, tofacitinib or vedolizumab.

100 elated QoL also improved significantly under golimumab treatment as indicated by increased IBDQ [mean

101 derwent both IGRA and TST screening prior to golimumab treatment.

102 or an intermediate-efficacy medication (eg, golimumab, ustekinumab, tofacitinib, filgotinib, and mir

103 C, the AGA recommends the use of infliximab, golimumab, vedolizumab, tofacitinib, upadacitinib, ustek

104 Golimumab was generally well tolerated.

105 Antibodies to golimumab were detected in 30 participants who received

106 r percentage of patients who received 100 mg golimumab were in clinical remission and had mucosal hea

107 ere infections (48% of patients treated with golimumab with or without MTX and 41% of patients receiv